Circular RNAs as Potential Theranostics in the Cardiovascular System

被引：54

作者：

Bei, Yihua ^{[1
]}

Yang, Tingting ^{[1
]}

Wang, Lijun ^{[1
]}

Holvoet, Paul ^{[2
]}

Das, Saumya ^{[3
,4
]}

Sluijter, Joost P. G. ^{[5
,6
]}

Monteiro, Marta Chagas ^{[7
]}

Liu, Yang ^{[8
]}

Zhou, Qiulian ^{[1
]}

Xiao, Junjie ^{[1
]}

机构：

[1] Shanghai Univ, Inst Cardiovasc Sci, Sch Life Sci, Cardiac Regenerat & Ageing Lab, 333 Nan Chen Rd, Shanghai 200444, Peoples R China

[2] Katholieke Univ Leuven, Expt Cardiol, Dept Cardiovasc Sci, B-3000 Leuven, Belgium

[3] Massachusetts Gen Hosp, Div Cardiovasc, Boston, MA 02114 USA

[4] Harvard Med Sch, Boston, MA 02114 USA

[5] Univ Med Ctr Utrecht, Lab Expt Cardiol, Dept Cardiol, NL-3508 GA Utrecht, Netherlands

[6] Univ Med Ctr Utrecht, UMC Utrecht Regenerat Med Ctr, NL-3508 GA Utrecht, Netherlands

[7] Fed Univ Para UFPA, Hlth Sci Inst, Pharmaceut Sci Postgrad Program, BR-66075900 Belem, Para, Brazil

[8] Tongji Univ, Sch Med, Tongji Hosp, Dept Cardiol, Shanghai 200065, Peoples R China

来源：

MOLECULAR THERAPY-NUCLEIC ACIDS | 2018年 / 13卷

基金：

中国国家自然科学基金;

关键词：

MYOCARDIAL-INFARCTION; NONCODING RNAS; CARDIAC DIFFERENTIATION; HEART-FAILURE; EXPRESSION; DATABASE; IDENTIFICATION; BIOGENESIS; ABUNDANT; CIRCRNA;

D O I：

10.1016/j.omtn.2018.09.022

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Cardiovascular diseases (CVDs) represent the largest contributor to mortality worldwide. Identification of novel therapeutic targets and biomarkers for CVDs is urgently needed. Circular RNAs (circRNAs) are endogenous, abundant, and stable non-coding RNAs formed by back-splicing events. Their role as regulators of gene expression has been increasingly reported. Notably, circRNAs mediate essential physiological and pathological processes in the cardiovascular system. Our first aim, therefore, is to summarize recent advances in the role of circRNAs in cardiac development as well as in pathogenesis of various CVDs. Because circRNAs are stable in circulation and their dynamic changes may reflect different disease stages, they are considered ideal biomarkers. Therefore, our second aim is to review studies that have identified circulating circRNAs as biomarkers for CVDs. Finally, we discuss the shortage of functional studies and the limitations of available clinical studies and provide future perspectives.

引用

页码：407 / 418

页数：12

共 76 条

[11] Long noncoding RNAs in cardiac development and ageing [J].